Adaptimmune and TCR2 Tx Complete Strategic Combination
On Thursday, June 1, Adaptimmune announced (press release) the completion of the strategic combination with TCR2 to form a preeminent cell therapy company to treat solid tumors. Moreover, the company hosted an event to elaborate on the newly established clinical milestones for all the assets in its pipeline (webcast / presentation) Below, Celltelligence provides insights on the approval of the merger by the companies’ shareholders, while discussing the future of its combined pipeline.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.